Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Bladder Cancer

  Free Subscription


09.12.2019

1 Adv Nutr
1 Aging (Albany NY)
1 Asian J Endosc Surg
1 Biosci Rep
2 BMC Cancer
1 BMC Urol
1 Can Urol Assoc J
1 Cancer Cell Int
1 Cancer Med
1 Cell Death Differ
3 Clin Genitourin Cancer
3 Curr Urol Rep
1 ESMO Open
1 Eur Rev Med Pharmacol Sci
1 Eur Urol
1 Expert Rev Mol Diagn
1 Front Oncol
1 Histol Histopathol
1 Int J Oncol
1 Int J Urol
1 J Cancer
1 J Cell Biochem
1 J Endourol
6 J Urol
2 Minerva Urol Nefrol
2 Neoplasma
1 Neurourol Urodyn
2 Onco Targets Ther
1 Oncol Lett
1 Pharmacol Res
1 PLoS One
1 Prog Urol
1 Rev Med Suisse
1 Ther Adv Med Oncol
1 Toxicol In Vitro
7 Urol Clin North Am
1 Urol Int


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Adv Nutr

  1. WU S, Liu Y, Michalek JE, Mesa RA, et al
    Carotenoid Intake and Circulating Carotenoids Are Inversely Associated with the Risk of Bladder Cancer: A Dose-Response Meta-analysis.
    Adv Nutr. 2019 Dec 4. pii: 5652213. doi: 10.1093.
    PubMed     Text format     Abstract available


    Aging (Albany NY)

  2. SU Y, Du Z, Zhong G, Ya Y, et al
    circ5912 suppresses cancer progression via inducing MET in bladder cancer.
    Aging (Albany NY). 2019;11.
    PubMed     Text format     Abstract available


    Asian J Endosc Surg

  3. ATAKA R, Sato S, Matsubara K, Takagi M, et al
    Small bowel obstruction due to internal hernia caused by the ureter after laparoscopic radical cystectomy and ileal conduit: A case report.
    Asian J Endosc Surg. 2019;12:189-191.
    PubMed     Text format     Abstract available


    Biosci Rep

  4. CHEN M, Nie ZY, Wen XH, Gao YH, et al
    m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer.
    Biosci Rep. 2019 Dec 6. pii: 221434. doi: 10.1042/BSR20192892.
    PubMed     Text format     Abstract available


    BMC Cancer

  5. BOURN J, Rathore K, Donnell R, White W, et al
    Detection of carcinogen-induced bladder cancer by fluorocoxib A.
    BMC Cancer. 2019;19:1152.
    PubMed     Text format     Abstract available

  6. WANG Z, Liu X, Liu X, Sun H, et al
    UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma.
    BMC Cancer. 2019;19:1195.
    PubMed     Text format     Abstract available


    BMC Urol

  7. BA M, Cui S, Long H, Gong Y, et al
    Development of a high-precision bladder hyperthermic intracavitary chemotherapy device for bladder cancer and pharmacokinetic study.
    BMC Urol. 2019;19:126.
    PubMed     Text format     Abstract available


    Can Urol Assoc J

  8. WISSING MD, Kassouf W, Tanguay S, Aprikian AG, et al
    The use of perioperative chemotherapy in patients undergoing radical cystectomy for bladder cancer in Quebec (Canada), 2000-2016.
    Can Urol Assoc J. 2019 Nov 29. pii: cuaj.6094. doi: 10.5489/cuaj.6094.
    PubMed     Text format     Abstract available


    Cancer Cell Int

  9. GUO J, Chen Z, Jiang H, Yu Z, et al
    The lncRNA DLX6-AS1 promoted cell proliferation, invasion, migration and epithelial-to-mesenchymal transition in bladder cancer via modulating Wnt/beta-catenin signaling pathway.
    Cancer Cell Int. 2019;19:312.
    PubMed     Text format     Abstract available


    Cancer Med

  10. ZHANG C, Shen K, Zheng Y, Qi F, et al
    Genome-wide screening of abberant methylated drivers combined with relative risk loci in bladder cancer.
    Cancer Med. 2019 Dec 3. doi: 10.1002/cam4.2665.
    PubMed     Text format     Abstract available


    Cell Death Differ

  11. GUO Y, Yuan X, Li K, Dai M, et al
    GABPA is a master regulator of luminal identity and restrains aggressive diseases in bladder cancer.
    Cell Death Differ. 2019 Dec 4. pii: 10.1038/s41418-019-0466.
    PubMed     Text format     Abstract available


    Clin Genitourin Cancer

  12. D'ANDREA D, Soria F, Abufaraj M, Pones M, et al
    Comparative Effectiveness of Intravesical BCG-Tice and BCG-Moreau in Patients With Non-muscle-invasive Bladder Cancer.
    Clin Genitourin Cancer. 2019 Nov 6. pii: S1558-7673(19)30325.
    PubMed     Text format     Abstract available

  13. LI X, Shu K, Zhou J, Yu Q, et al
    Preoperative Plasma Fibrinogen and D-dimer as Prognostic Biomarkers for Non-Muscle-Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2019 Nov 6. pii: S1558-7673(19)30329.
    PubMed     Text format     Abstract available

  14. RADKIEWICZ C, Edgren G, Johansson ALV, Jahnson S, et al
    Sex Differences in Urothelial Bladder Cancer Survival.
    Clin Genitourin Cancer. 2019 Nov 6. pii: S1558-7673(19)30324.
    PubMed     Text format     Abstract available


    Curr Urol Rep

  15. GURRAM S, Muthigi A, Egan J, Stamatakis L, et al
    Imaging in Localized Bladder Cancer: Can Current Diagnostic Modalities Provide Accurate Local Tumor Staging?
    Curr Urol Rep. 2019;20:82.
    PubMed     Text format     Abstract available

  16. PACKIAM VT, Werntz RP, Steinberg GD
    Current Clinical Trials in Non-muscle-Invasive Bladder Cancer: Heightened Need in an Era of Chronic BCG Shortage.
    Curr Urol Rep. 2019;20:84.
    PubMed     Text format     Abstract available

  17. ARON M
    Variant Histology in Bladder Cancer-Current Understanding of Pathologic Subtypes.
    Curr Urol Rep. 2019;20:80.
    PubMed     Text format     Abstract available


    ESMO Open

  18. LIM JH, Sundar S
    Prognosis of early stage small cell bladder cancer is not always dismal.
    ESMO Open. 2019;4:e000559.
    PubMed     Text format     Abstract available


    Eur Rev Med Pharmacol Sci

  19. YU X, Wang ZL, Han CL, Wang MW, et al
    LncRNA CASC15 functions as an oncogene by sponging miR-130b-3p in bladder cancer.
    Eur Rev Med Pharmacol Sci. 2019;23:9814-9820.
    PubMed     Text format     Abstract available


    Eur Urol

  20. WILLIAMS SB, Black PC, Dyrskjot L, Seiler R, et al
    Re: Aurelie Kamoun, Aurelien de Reynies, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.09.006: A Statement from the International Bladder Cancer Ne
    Eur Urol. 2019 Nov 28. pii: S0302-2838(19)30874.
    PubMed     Text format    


    Expert Rev Mol Diagn

  21. LOPEZ-BELTRAN A, Cheng L, Gevaert T, Blanca A, et al
    Current and emerging bladder cancer biomarkers with an emphasis on urine biomarkers.
    Expert Rev Mol Diagn. 2019 Dec 4. doi: 10.1080/14737159.2020.1699791.
    PubMed     Text format     Abstract available


    Front Oncol

  22. SATYAL U, Srivastava A, Abbosh PH
    Urine Biopsy-Liquid Gold for Molecular Detection and Surveillance of Bladder Cancer.
    Front Oncol. 2019;9:1266.
    PubMed     Text format     Abstract available


    Histol Histopathol

  23. SANGUEDOLCE F, Cormio L, Carrieri G, Calo B, et al
    Role of androgen receptor expression in non-muscle-invasive bladder cancer: a systematic review and meta-analysis.
    Histol Histopathol. 2019 Dec 5:18189. doi: 10.14670.
    PubMed     Text format     Abstract available


    Int J Oncol

  24. XU M, Gu M, Zhou J, Da J, et al
    Interaction of YAP1 and mTOR promotes bladder cancer progression.
    Int J Oncol. 2019 Nov 25. doi: 10.3892/ijo.2019.4922.
    PubMed     Text format     Abstract available


    Int J Urol

  25. KIKUCHI E, Hayakawa N, Fukumoto K, Shigeta K, et al
    Bacillus Calmette-Guerin-unresponsive non-muscle-invasive bladder cancer: Its definition and future therapeutic strategies.
    Int J Urol. 2019 Dec 3. doi: 10.1111/iju.14153.
    PubMed     Text format     Abstract available


    J Cancer

  26. ZHANG N, Chen S, Wu L, Wu Y, et al
    Identification of Cancer-Specific Methylation of Gene Combination for the Diagnosis of Bladder Cancer.
    J Cancer. 2019;10:6761-6766.
    PubMed     Text format     Abstract available


    J Cell Biochem

  27. PENG W, Dong N, Wu S, Gui D, et al
    miR-4500 suppresses cell proliferation and migration in bladder cancer via inhibition of STAT3/CCR7 pathway.
    J Cell Biochem. 2019 Dec 1. doi: 10.1002/jcb.29558.
    PubMed     Text format     Abstract available


    J Endourol

  28. IKEDA A, Nosato H, Kochi Y, Kojima T, et al
    Support system of cystoscopic diagnosis for bladder cancer based on artificial intelligence.
    J Endourol. 2019 Dec 6. doi: 10.1089/end.2019.0509.
    PubMed     Text format     Abstract available


    J Urol

  29. SCHAEFFER EM
    Re: Reduced Recurrence of Low-Grade Papillary Bladder Tumors Associated with Asymptomatic Bacteriuria.
    J Urol. 2019;202:849.
    PubMed     Text format    

  30. CHANG SS
    Re: Radiofrequency-Induced Thermo-Chemotherapy Effect versus a Second Course of Bacillus Calmette-Guerin or Institutional Standard in Patients with Recurrence of Non-Muscle-Invasive Bladder Cancer following Induction or Maintenance Bacillus Calmette-G
    J Urol. 2019 Dec 3:101097JU0000000000000676. doi: 10.1097/JU.0000000000000676.
    PubMed     Text format    

  31. SINGLA N
    Editorial Comment.
    J Urol. 2019;202:688.
    PubMed     Text format    

  32. ATALA A
    Re: Recurrent Activating Mutations of PPARgamma Associated with Luminal Bladder Tumors.
    J Urol. 2019;202:869.
    PubMed     Text format    

  33. SEFIK E, Bozkurt IH, Basmaci I, Celik S, et al
    Re: Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial.
    J Urol. 2019;202:819.
    PubMed     Text format    

  34. LUO Y, Wang X, Xiao Y
    Re: Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial.
    J Urol. 2019;202:819-820.
    PubMed     Text format    


    Minerva Urol Nefrol

  35. HURLE R, Lazzeri M, Saita A, Naselli A, et al
    Predictive factors for progression of patients with carcinoma in situ of the bladder at long-term follow-up: pure versus non-pure CIS.
    Minerva Urol Nefrol. 2019;71:406-412.
    PubMed     Text format     Abstract available

  36. GIANNARINI G, Crestani A, Inferrera A, Rossanese M, et al
    Impact of enhanced recovery after surgery protocols versus standard of care on perioperative outcomes of radical cystectomy: a systematic review and meta-analysis of comparative studies.
    Minerva Urol Nefrol. 2019;71:309-323.
    PubMed     Text format     Abstract available


    Neoplasma

  37. SONG Z, Zhang Q, Zhu J, Yin G, et al
    Identification of urinary hsa_circ _0137439 as potential biomarker and tumor regulator of bladder cancer.
    Neoplasma. 2019 Nov 18. pii: 181214N970. doi: 10.4149/neo_2018_181214.
    PubMed     Text format     Abstract available

  38. SOUKUP V, Capoun O, Pesl M, Vavrova L, et al
    The significance of calprotectin, CD147, APOA4 and DJ-1 in non-invasive detection of urinary bladder carcinoma.
    Neoplasma. 2019;66:1019-1023.
    PubMed     Text format     Abstract available


    Neurourol Urodyn

  39. LIU Y, Wu G
    NNT-AS1 enhances bladder cancer cell growth by targeting miR-1301-3p/PODXL axis and activating Wnt pathway.
    Neurourol Urodyn. 2019 Nov 29. doi: 10.1002/nau.24238.
    PubMed     Text format     Abstract available


    Onco Targets Ther

  40. TAN S, Bian X, Wu B, Chen X, et al
    RASSF6 Is Downregulated In Human Bladder Cancers And Regulates Doxorubicin Sensitivity And Mitochondrial Membrane Potential Via The Hippo Signaling Pathway.
    Onco Targets Ther. 2019;12:9189-9200.
    PubMed     Text format     Abstract available

  41. LI Y, Chen R, Li Z, Cheng H, et al
    miR-204 Negatively Regulates Cell Growth And Metastasis By Targeting ROBO4 In Human Bladder Cancer.
    Onco Targets Ther. 2019;12:8515-8524.
    PubMed     Text format     Abstract available


    Oncol Lett

  42. CHO CJ, Yang CW, Wu CL, Ho JY, et al
    The modulation study of multiple drug resistance in bladder cancer by curcumin and resveratrol.
    Oncol Lett. 2019;18:6869-6876.
    PubMed     Text format     Abstract available


    Pharmacol Res

  43. WANG J, Tan X, Guo Q, Lin X, et al
    FGF9 inhibition by a novel binding peptide has efficacy in gastric and bladder cancer per se and reverses resistance to cisplatin.
    Pharmacol Res. 2019 Dec 2:104575. doi: 10.1016/j.phrs.2019.104575.
    PubMed     Text format     Abstract available


    PLoS One

  44. HE S, Carman CV, Lee JH, Lan B, et al
    The tumor suppressor p53 can promote collective cellular migration.
    PLoS One. 2019;14:e0202065.
    PubMed     Text format     Abstract available


    Prog Urol

  45. MARQUETTE T, Walz J, Rybikowski S, Maubon T, et al
    [Safety of Hyperthermic IntraVEsical Chemotherapy (HIVEC) for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients].
    Prog Urol. 2019 Nov 28. pii: S1166-7087(19)30609.
    PubMed     Text format     Abstract available


    Rev Med Suisse

  46. BOSSHARD P, Roth B
    [Cisplatin-based chemotherapy in muscle-invasive bladder cancer: soon outdated ?]
    Rev Med Suisse. 2019;15:2190-2194.
    PubMed     Text format     Abstract available


    Ther Adv Med Oncol

  47. CASADEI C, Dizman N, Schepisi G, Cursano MC, et al
    Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors.
    Ther Adv Med Oncol. 2019;11:1758835919890285.
    PubMed     Text format     Abstract available


    Toxicol In Vitro

  48. HSU YH, Huang HP, Chang HR
    The uremic toxin p-cresol promotes the invasion and migration on carcinoma cells via Ras and mTOR signaling.
    Toxicol In Vitro. 2019;58:126-131.
    PubMed     Text format     Abstract available


    Urol Clin North Am

  49. HAAS CR, McKiernan JM
    Salvage Therapy Using Bacillus Calmette-Guerin Derivatives or Single Agent Chemotherapy.
    Urol Clin North Am. 2020;47:47-54.
    PubMed     Text format     Abstract available

  50. BROOKS NA, O'Donnell MA
    Combination Intravesical Therapy.
    Urol Clin North Am. 2020;47:83-91.
    PubMed     Text format     Abstract available

  51. NARAYAN VM, Dinney CPN
    Intravesical Gene Therapy.
    Urol Clin North Am. 2020;47:93-101.
    PubMed     Text format     Abstract available

  52. LI R, Kamat AM
    Predictors of Response to Intravesical Therapy.
    Urol Clin North Am. 2020;47:23-33.
    PubMed     Text format     Abstract available

  53. BECKER REN, Kates MR, Bivalacqua TJ
    Identification of Candidates for Salvage Therapy: The Past, Present, and Future of Defining Bacillus Calmette-Guerin Failure.
    Urol Clin North Am. 2020;47:15-21.
    PubMed     Text format     Abstract available

  54. KONETY BR, Narayan VM, Dinney CPN
    Bacillus Calmette-Guerin Salvage Therapy: Definitions and Context.
    Urol Clin North Am. 2020;47:1-4.
    PubMed     Text format     Abstract available

  55. TAN WP, Longo TA, Inman BA
    Heated Intravesical Chemotherapy: Biology and Clinical Utility.
    Urol Clin North Am. 2020;47:55-72.
    PubMed     Text format     Abstract available


    Urol Int

  56. ZIEGELMUELLER BK, Jokisch JF, Buchner A, Grimm T, et al
    Long-Term Follow-Up and Oncological Outcome of Patients Undergoing Radical Cystectomy for Bladder Cancer following an Enhanced Recovery after Surgery (ERAS) Protocol: Results of a Large Randomized, Prospective, Single-Center Study.
    Urol Int. 2019 Dec 4:1-7. doi: 10.1159/000504236.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: